Earning Analysis
Welcome to our in-depth analysis of Halozyme Therapeutics Inc(HALO) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Halozyme Therapeutics Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
| FY2025Q3 | 2025-11-03 | After Hours | 1.59 | 1.72 | +8.18 | 339.10M | 354.26M | +4.47 | +2.79 | +3.08 |
| FY2025Q2 | 2025-08-05 | After Hours | 1.23 | 1.54 | +25.20 | 285.92M | 325.72M | +13.92 | +2.48 | +3.42 |
| FY2025Q1 | 2025-05-06 | After Hours | 0.94 | 1.11 | +18.09 | 230.18M | 264.86M | +15.07 | +18.12 | +12.13 |
| FY2024Q4 | 2025-02-18 | After Hours | 1.16 | 1.26 | +8.62 | 285.74M | 298.01M | +4.29 | -0.22 | +0.16 |
| FY2024Q3 | 2024-10-31 | After Hours | 0.98 | 1.27 | +29.59 | 252.17M | 290.08M | +15.04 | +13.01 | +17.96 |
| FY2024Q2 | 2024-08-06 | - | 0.73 | 0.85 | +16.44 | 204.94M | 231.35M | +12.89 | -0.33 | +7.60 |
| FY2024Q1 | 2024-05-07 | - | 0.64 | 0.71 | +10.94 | 199.65M | 195.88M | -1.89 | +0.86 | +6.73 |
| FY2023Q4 | 2024-02-20 | - | 0.77 | 0.75 | -2.60 | 231.14M | 230.04M | -0.48 | -0.28 | +9.89 |
| FY2023Q3 | 2023-11-06 | - | 0.67 | 0.69 | +2.99 | 216.11M | 216.03M | -0.04 | -0.90 | +4.69 |
| FY2023Q2 | 2023-08-08 | - | 0.59 | 0.68 | +15.25 | 199.95M | 221.04M | +10.55 | +3.09 | +4.40 |
HALO Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Halozyme Therapeutics Inc reported performance for FY2025Q3, announced on 2025-11-03. The company achieved an EPS of 1.72, compared to analyst estimates of 1.59 by 8.18% . Revenue for the quarter reached 354.26M compared to expectations of 339.10M by 4.47% .
The stock price reacted with a 2.79% one-day change and a 3.08% five-day change following the earnings release. These movements reflect market reaction in Halozyme Therapeutics Inc growth trajectory and strategic initiatives.
HALO Earnings Forecast
Looking ahead, Halozyme Therapeutics Inc(HALO) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q4 project quarter revenue of 398.22M and an EPS of 1.90.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 1.71%, while EPS estimates have been Revise Upward by 1.41%. For the upcoming Q4 2025, revenue estimates have been adjusted Revise Upward by 1.53% . These revisions correlate with a -15.99% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Halozyme Therapeutics Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between HALO's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Upward
+1.71%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+1.41%
In Past 3 Month
Revenue Estimates for Q4 2025
Revise Upward
+1.53%
In Past 3 Month
Stock Price
Go Down
-15.99%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:1.34B
--
EPS Estimate-Annual FY 2025:6.14
—
Stock Price62.95
HALO Revenue and EPS Performance: A Historical Perspective
Halozyme Therapeutics Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q3 (2025-11-03,After Hours):
EPS: 1.72 (Actual) vs.1.59 (Estimate) (8.18%)
Revenue: 354.26M (Actual) vs. 339.10M (Estimate) (4.47%)
Price Reaction: 2.79%(1-Day), 3.08%(5-Day)
FY2025Q2 (2025-08-05,After Hours):
EPS: 1.54 (Actual) vs.1.23 (Estimate) (25.20%)
Revenue: 325.72M (Actual) vs. 285.92M (Estimate) (13.92%)
Price Reaction: 2.48%(1-Day), 3.42%(5-Day)
FY2025Q1 (2025-05-06,After Hours):
EPS: 1.11 (Actual) vs.0.94 (Estimate) (18.09%)
Revenue: 264.86M (Actual) vs. 230.18M (Estimate) (15.07%)
Price Reaction: 18.12%(1-Day), 12.13%(5-Day)
Earnings Reaction
The chart below shows how HALO performed 10 days before and after its earnings report, based on data from the past quarters. Typically, HALO sees a -1.41% change in stock price 10 days leading up to the earnings, and a +7.37% change 10 days following the report. On the earnings day itself, the stock moves by +0.26%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed 2.79% on the day following the earnings release and then changed by 6.59% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Halozyme Therapeutics Inc (HALO) Q3 2025 Earnings Call Summary
Positive
2025-11-03
The earnings call summary reflects strong financial guidance, optimistic product development projections, and a strategic shareholder return plan. Despite some uncertainties in the Q&A, such as unclear patient growth sources for OCREVUS and lack of updates on certain products, the overall sentiment remains positive due to increased guidance, strong royalty contributions, and potential new partnerships. The stock is likely to experience a positive movement, with the potential for further upside if new deals materialize.
Halozyme Therapeutics Inc (HALO) Q2 2025 Earnings Call Summary
Positive
2025-08-06
The earnings call summary indicates strong financial performance with significant year-over-year growth in revenue and EPS guidance. The company is actively engaging in M&A and share repurchase plans, which are positive signals. While there are ongoing litigations, management appears confident in their positions. The Q&A reveals strong market interest in their products and positive trends in product adoption. Overall, the sentiment is positive with potential upward stock movement.
Halozyme Therapeutics Inc (HALO) Q1 2025 Earnings Call Summary
Positive
2025-05-07
The earnings call summary shows strong financial performance with record high revenue and optimistic guidance. The Q&A reveals confidence in legal outcomes and continued product strength. Share repurchases add to shareholder value. Despite some uncertainties in litigation and market conditions, the overall sentiment is positive, suggesting a likely stock price increase.
Halozyme Therapeutics Inc (HALO) Q1 2025 Earnings Call Summary
Positive
2025-05-06
The earnings call highlights strong financial performance with record high revenue and significant growth in key metrics. The positive projections for 2025 and beyond, along with a robust share repurchase plan, contribute to a positive outlook. The Q&A section reveals confidence in ongoing litigation and minimal impact from external risks, further supporting a positive sentiment. Despite minor concerns about pricing pressure, the overall sentiment is positive due to strong product performance and optimistic guidance.
Halozyme Therapeutics Inc (HALO) Q1 2025 Earnings Call Summary
Positive
2025-05-06
The earnings call reveals strong financial performance with significant revenue and earnings growth. The company also offers optimistic guidance for 2025, projecting robust revenue and EBITDA growth. The ongoing share buyback program is likely to positively influence stock prices. Although there are some uncertainties regarding patent litigation and new partnerships, management seems confident in overcoming these challenges. The Q&A section did not reveal any major concerns that could negatively impact the stock. Overall, the positive financial outlook and shareholder returns suggest a positive stock price movement over the next two weeks.
Halozyme Therapeutics Inc (HALO) Q4 2024 Earnings Call Summary
Positive
2025-02-19
The earnings call shows strong financial performance with record revenue, significant EPS growth, and an optimistic outlook. The Q&A section reveals confidence in future partnerships and revenue streams, though some uncertainties remain. The ASR plan and strong financial metrics suggest a positive stock reaction.
Halozyme Therapeutics, Inc. (HALO) Q3 2024 Earnings Call Summary
Positive
2024-10-31
The earnings call summary indicates strong financial performance, with significant revenue and EPS growth, driven by successful product launches and collaborations. Despite some risks in market adoption and IP protection, the company's raised guidance for royalty revenues and EBITDA reflects confidence. The Q&A session revealed strategic plans for market expansion and collaboration, supporting a positive outlook. The overall sentiment is positive, with expectations of continued growth and profitability, suggesting a likely stock price increase of 2% to 8% over the next two weeks.
Halozyme Therapeutics, Inc. (HALO) Q2 2024 Earnings Call Summary
Positive
2024-08-07
The earnings call summary shows strong financial performance with significant growth in revenue, royalty revenue, EBITDA, and EPS. The optimistic guidance for 2024, along with a new $750 million share repurchase program, suggests confidence in future performance. While there are risks like competitive pressures and regulatory issues, the company is actively pursuing partnerships and M&A opportunities. The Q&A section reveals positive sentiment towards partnership activities and potential growth. Despite some uncertainty in management responses, the overall outlook supports a positive stock price movement.
People Also Watch
FAQ
What were the key highlights of HALO’s latest earnings report for FY2025Q3?
How did HALO’s stock price react after the FY2025Q3 earnings release?
What are the revenue and EPS estimates for HALO for 2025/Q4?
How does HALO’s stock price correlate with earnings forecast revisions?
What should investors expect from HALO’s next earnings report?